dc.creator | Chiou, George C. Y. | |
dc.date.accessioned | 2019-06-17T17:02:35Z | |
dc.date.available | 2019-06-17T17:02:35Z | |
dc.date.issued | 1988-09-20 | |
dc.identifier.uri | https://hdl.handle.net/1969.1/176864 | |
dc.description.abstract | Aqueous humor formation and intraocular pressure in mammals having ocular hypertension or glaucoma may be reduced by topically administering to a hypertensive eye an ophthalmologically acceptable amount of certain dopamine antagonists or acid addition salts thereof. A preferred group of dopamine antagonists is the 4-piperidino-4-fluoro-butyrophenones, especially haloperidol, trifluperidol, and moperone. The phenothiazines are another suitable group of dopamine antagonists. An ophthalmic composition for topically treating glaucoma may comprise an aqueous solution containing 0.01% to 5% by weight of a water-soluble ophthalmologically acceptable acid addition salt of such dopamine antagonist. | en |
dc.language | eng | |
dc.publisher | United States. Patent and Trademark Office | |
dc.rights | Public Domain (No copyright - United States) | en |
dc.rights.uri | http://rightsstatements.org/vocab/NoC-US/1.0/ | |
dc.title | Treatment of ocular hypertension and glaucoma with dopamine antagonists | en |
dc.type | Utility patent | en |
dc.format.digitalOrigin | reformatted digital | en |
dc.description.country | US | |
dc.contributor.assignee | The Texas A & M University System | |
dc.identifier.patentapplicationnumber | 07/094968 | |
dc.subject.uspcprimary | 514/322 | |
dc.subject.uspcother | 514/913 | |
dc.date.filed | 1987-09-09 | |
dc.publisher.digital | Texas A&M University. Libraries | |
dc.subject.cpcprimary | A61K 31/445 | |
dc.subject.cpcprimary | Y10S 514/913 | |